Key Takeaways
- Revenue surged 19% YoY, margin nearly doubled: Revenue hit ₹166 crores while EBITDA margin jumped to 39% from 23% YoY, driven by backward integration and a strategic shift toward higher-priced regulated markets.
- The export mix is transforming: Export share rose to 83%, with LATAM alone jumping to 19% from 13% YoY. The company now classifies LATAM as a regulated market after clearing an ANVISA Brazil audit with zero observations.
- Capacity is set to nearly double: Module E validation is complete and commercial production starts Q3 FY25, taking total capacity to ~1,020 KL. Full utilization is expected by the FY27 exit, though management declined to quantify the revenue potential.
- New products and CMO deals are loading into H2: New products launch in Q3 with full effect from Q4, while at least 3–4 API advanced intermediate CMO opportunities and Ambernath formulation revenue begin contributing from Q4 or Q1 next year.
- What to watch next quarter: The pace of Module E's commercial ramp-up, initial traction on new product launches in semi-regulated markets, and whether the DSM food-grade volumes begin flowing after the recent FSSAI approval.
Margin Transformation
- Backward integration is the engine: 15 products are now backward integrated to the basic chemical stage, eliminating dependence on outsourced advanced intermediates. This structural shift, combined with better realizations in regulated markets, lifted gross margins from the 60s to the 70s.
- Quarterly volatility is expected, annual trend is the signal: Management flagged that Q3 and Q4 will see some margin dilution as new products launch first in lower-priced semi-regulated markets before maturing into regulated ones. On an annualized basis, the margin trend is expected to stabilize between 32% and 34%.
- Operating costs are rising alongside the ramp: Despite 72% gross margins, EBITDA margins stayed in line with the prior quarter because of higher operating costs from formulation and R&D hiring, plus ongoing new plant validations. Module E alone will add a couple of crores per quarter in OpEx.
- Absolute profit growth is the commitment: Management emphasized that year-on-year growth in absolute EBITDA and PAT will be clearly visible, even if percentage margins fluctuate quarter to quarter as the portfolio diversifies.
Saloni Wagh: "on that annualized basis, we are expecting our margin trend to be somewhere between that 32% to 34% moving forward. And year-on-year, definitely you will see that in terms of the actual growth in the EBITDA number and the PAT number that you will be able to see very clearly."
Capacity Expansion & Module E
- Capacity nearly doubles to ~1,020 KL: Module E adds roughly 500 KL to the existing ~550 KL base, with validation completed and commercial production anticipated by Q3 FY25. The facility is multipurpose, so revenue potential depends on the product mix loaded into it, a detail management declined to quantify.
- Ramp-up is a multi-year story: Management expects Module E to take 1.5 to 2 years to reach maximum utilization, with full capacity utilization targeted by the end of FY27 on an exit quarterly basis. Solar power has already been initialized to provide some operating cost savings.
- Legacy asset repairs are also in the pipeline: Modules A, B, and C will require repairs totaling around ₹100 crores over phases, alongside normal maintenance CAPEX. The next wave of expansion at the Patalganga site is roughly 2.5 to 3 years out.
- Capacity reconciliation was left unresolved: An analyst attempted to reconcile the disclosed capacity figures with the 1,020 KL total and could not get the numbers to match, taking the matter offline.
Export Mix & Regulated Market Shift
- LATAM is the breakout region: LATAM's revenue share jumped to 19% from 13% YoY, with positive momentum also noted in North America and Africa. The company now classifies LATAM as a regulated market, citing ANVISA's standards as comparable to USFDA, Health Canada, and EDQM.
- Brazil is the anchor: The company has extensive registrations for at least 9 products in Brazil and cleared an ANVISA audit with zero observations earlier this year. Similar revenue growth trends are expected as other products gain traction in the region.
- Regulated markets command higher prices: The margin profile in regulated markets is higher than in semi-regulated ones, and LATAM is now grouped into that higher-margin bucket. Management declined to provide country- or region-specific margin breakdowns.
- China NMPA audit is the next regulatory milestone: Scheduled for December, this audit represents the next test of the company's regulatory standing. The last USFDA audit was in FY20, and no immediate USFDA audit is anticipated.
Dr. Satish Wagh: "we are confident that we are telling our customers, please don't ask for any reduction in the price. This is our ideology because you should be happy that rather than a non-GMP plant, you are buying the material, even intermediate API from a US FDA plant."
New Products & Pipeline
- New products launch in Q3, full effect from Q4: The new products target categories with extremely high global volumes and heavy dependence on a single manufacturer, so good volume traction is expected upon launch. Initial uptake will come in semi-regulated markets before the products mature into regulated ones.
- New products could reach 15% of topline in ~2 years: Management expects these launches to contribute meaningfully, with the full effect of the new product philosophy becoming visible from Q4 of this year.
- DSM project is a multi-phase, multi-year opportunity: Feed application has already launched without needing regulatory approvals. Food application just received FSSAI approval last week, enabling volumes next year. Pharma volumes require 2 years for CEP, US DMF, and Japanese DMF, with peak volume in three years. The ₹50–60 crore annual potential by FY27 may prove conservative.
- DSM could unlock larger deals: Once confidence is established on the initial project, larger opportunities are possible. DSM has sold off its API plants and wants to concentrate on the vitamin sector; preliminary discussions for another project have already taken place.
- Cancer detection kit is a 3-year horizon: International patent filings are underway for Korea, Thailand, Indonesia, and the Philippines, with filing activity expected to complete in the next 2–3 months. Clinical trials follow, with commercialization expected in 2–3 years.
CMO-CDMO & Ambernath
- European CMO contribution begins in Q3: CMO-CDMO opportunities are progressing well, with one European engagement already starting to contribute revenue that will reflect in Q3. The full effect of the CMO-CDMO pipeline is expected to be visible in the next 2 years.
- API advanced intermediate deals are loading: At least 3–4 opportunities are expected to start commercial revenue from Q4 of this year or Q1 of the next financial year. Margins on these contract manufacturing opportunities are in line with the current profile.
- Ambernath formulation is nearing revenue: The site is a pure contract manufacturing play, not an own-label operation. Formulation revenue is expected from Q4 of this year or Q1 of next year, with margins expected to be even better than the current profile.
- Whey protein project awaits FSSAI license: The FSSAI license is expected by the end of Q3, which would unlock another new product stream.
Competitive Moat & Strategy
- The China-GMP gap is a structural advantage: Supriya targets products supplied from China to the world, where Chinese plants are non-GMP. As more countries like those in Latin America begin requiring GMP, the company positions itself as the GMP-compliant alternative with end-to-end capability from basic chemicals.
- No single raw material dependency: Each product has its own starting raw material, and the company is backward integrated to the basic chemical stage. The chemicals used are widely available across industries, insulating the company from supplier concentration risk.
- The portfolio philosophy is deliberate: Supriya does not manufacture products already made in India, instead focusing on products where China is the dominant supplier to global markets. This niche strategy targets high-margin opportunities with limited domestic competition.
Dr. Satish Wagh: "if you say and go to them and put GMP, they will not get GMP for another 10 years. That much we know because we have been going to China for at least not less than 25 years."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 20%+ YoY | Ongoing annual target |
| H2 outperformance | H2 revenue slightly higher than H1; absolute EBITDA and PAT highest so far this year | FY25 H2 |
| Annualized EBITDA margin | 32% to 34% | Moving forward, stabilized basis |
| Module E commercial start | Commercial production begins | Q3 FY25 |
| Module E full utilization | Maximum capacity utilization reached | FY27 exit (quarterly basis) |
| New products launch | Initial traction in semi-regulated markets | Q3 FY25 |
| New products contribution | ~15% of topline | In about 2 years |
| DSM food volumes | Feed and food volumes begin | Next year (FY26) |
| DSM pharma peak volume | ₹50–60 crore annual run-rate, potentially higher | FY27, peak in 3 years |
| API advanced intermediate CMO | 3–4 opportunities start commercial revenue | Q4 FY25 or Q1 FY26 |
| Ambernath formulation revenue | Commercial revenue begins | Q4 FY25 or Q1 FY26 |
| Cancer detection kit commercialization | Commercial revenue begins | In next 2–3 years |
| FY27 revenue base case | ₹1,000 crore (conservative; upsides not yet budgeted) | FY27 |
| China NMPA audit | Scheduled | December 2024 |
| Whey protein FSSAI license | Expected | End of Q3 FY25 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹166 cr, +19% YoY from ₹140 cr in Q2 FY24 |
| H1 FY25 revenue | ₹327 cr, +20% YoY from ₹272 cr in H1 FY24 |
| EBITDA | ₹64.7 cr, doubled from ₹31.7 cr in Q2 FY24 |
| EBITDA margin | 39%, up from 23% in Q2 FY24 |
| H1 FY25 EBITDA | ₹127.3 cr, +68% YoY from ₹76 cr in H1 FY24 |
| PAT | ₹46 cr, nearly doubled from ₹24 cr in Q2 FY24 |
| PAT margin | 28%, up from 17% in Q2 FY24 |
| H1 FY25 PAT | ₹91 cr, +73% YoY from ₹52 cr in H1 FY24 |
| Annualized asset turnover ratio | 2.2, up from 2.1 in the prior period |
| Debt-to-equity ratio | 0.01 |
| Export contribution | 83% of revenue, up from 81% in Q2 FY24 |
| LATAM share of revenue | 19%, up from 13% in Q2 FY24 |
| Regulated markets share | ~52% to 53% of total revenue |
| Backward integrated products | 15 products, generating 74% of revenue, up from 69% last quarter |
| Total production capacity | ~1,020 KL (540 KL existing + ~400 KL module E + ~70 KL Ambernath) |
| Capacity utilization (pre-module E) | 76%+ |
| FY27 revenue guidance | ₹1,000 cr (base case) |
| Annualized EBITDA margin guidance | 32% to 34% moving forward |
| Revenue growth guidance | 20%+ year-on-year |
| New products contribution (2 years out) | ~15% of topline (per an analyst's math) |
| DSM project annual revenue potential | ₹50–₹60 cr starting FY27, with upside potential |
| CAPEX for module A, B, C repairs | ~₹100 cr, to be taken over phases |